Published in:
Open Access
30-09-2023 | Omalizumab | Review
Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status
Authors:
Thomas B. Casale, Ana Maria Gimenez-Arnau, Jonathan A. Bernstein, Michael Holden, Torsten Zuberbier, Marcus Maurer
Published in:
Dermatology and Therapy
|
Issue 11/2023
Login to get access
Abstract
Chronic spontaneous urticaria (CSU) is a debilitating inflammatory disorder of the skin, characterized by a fluctuating natural history, a complex mechanism of action, and a significant burden on patients, including effect on quality of life, development of psychosocial disorders, and a range of comorbidities. Recent international guidelines recommend a therapeutic approach of first-line treatment with second generation H1-antihistamines and second-line treatment with the biologic omalizumab. Here, the salient aspects of CSU and current status of data for omalizumab for patients with CSU are reviewed, with a focus on mechanism of action, efficacy and real-world effectiveness (including patient outcomes, response, relapse, and remission), and safety (including consideration of the risk of anaphylaxis). The review also considers recent data on COVID-19, CSU, and omalizumab and presents our perspective on future needs. Overall, the data suggest that omalizumab is an effective and well-tolerated treatment for patients with CSU that provides benefits for a wide range of patients.